This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Apr;77(4):335-6; author reply 336.

doi: 10.1016/j.clpt.2005.01.012.

Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status

PMID: 15903131
DOI: 10.1016/j.clpt.2005.01.012

Comment

Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status

Mike Ufer. Clin Pharmacol Ther. 2005 Apr.

. 2005 Apr;77(4):335-6; author reply 336.

doi: 10.1016/j.clpt.2005.01.012.

Author

PMID: 15903131
DOI: 10.1016/j.clpt.2005.01.012

No abstract available

PubMed Disclaimer

Comment on

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A. Schalekamp T, et al. Clin Pharmacol Ther. 2004 Nov;76(5):409-17. doi: 10.1016/j.clpt.2004.08.006. Clin Pharmacol Ther. 2004. PMID: 15536456

Similar articles

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A. Schalekamp T, et al. Clin Pharmacol Ther. 2004 Nov;76(5):409-17. doi: 10.1016/j.clpt.2004.08.006. Clin Pharmacol Ther. 2004. PMID: 15536456
Determination of bleeding risk using genetic markers in patients taking phenprocoumon.
Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM. Hummers-Pradier E, et al. Eur J Clin Pharmacol. 2003 Jul;59(3):213-9. doi: 10.1007/s00228-003-0580-8. Epub 2003 May 1. Eur J Clin Pharmacol. 2003. PMID: 12728288
Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M, Kammerer B, Kahlich R, Kirchheiner J, Yasar U, Brockmöller J, Rane A. Ufer M, et al. Xenobiotica. 2004 Sep;34(9):847-59. doi: 10.1080/00498250400009197. Xenobiotica. 2004. PMID: 15742978
Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Beinema M, et al. Thromb Haemost. 2008 Dec;100(6):1052-7. Thromb Haemost. 2008. PMID: 19132230 Review.
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M. Ufer M. Clin Pharmacokinet. 2005;44(12):1227-46. doi: 10.2165/00003088-200544120-00003. Clin Pharmacokinet. 2005. PMID: 16372822 Review.

See all similar articles

Cited by

Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
Abduljalil K, Lazar S, Natanzon M, Wu W, Zadoyan G, Steffens B, Kohl V, Mörike K, Tomalik-Scharte D, Stingl J, Schwab M, Harenberg J, Gleiter C, Fuhr U. Abduljalil K, et al. Clin Pharmacokinet. 2013 May;52(5):359-71. doi: 10.1007/s40262-013-0043-z. Clin Pharmacokinet. 2013. PMID: 23519598 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information